Over the recent quarter, the BlackRock Health Sciences Term Trust increased its investments in pharmaceutical and biotechnology companies, initiating new positions in GSK and Vertex Pharmaceuticals due to strong fundamentals and progress in rare disease treatments. Meanwhile, the Trust reduced its holdings in medical devices and supplies firms to lock in profits. This shift reflects a strategic focus on sectors with promising growth potential, which may impact the Trust's future performance and distribution rates.
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
The FTSE 100 rose modestly by 21 points to 10,459, supported by consumer defensive stocks like Bunzl and AstraZeneca, despite heavy losses in miners and tech funds. US and Asian tech stocks, including AI and semiconductor firms, sold off sharply, wit...
